Sun Pharmaceutical Industries Ltd. has reinforced its position as a leader in the Indian pharmaceutical space, reporting strong numbers following its Q2 results despite losses from its Taro subsidiary and adverse currency movements dragging down parts of its international business.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?